Results 21 to 30 of about 39,201 (181)

Modification of Remdesivir as a Better Inhibitor of COVID-19: A Computational Docking Study [PDF]

, 2020
Coronavirus (COVID-19) mediated infection is a highly contagious respiratory illness that was initially found in Wuhan city of Hubei Province in China. The ongoing pandemic of the novel SARS-CoV-2 virus is affecting global health.
Md. Lutful, Kabir, Tasnin, Al Hasib, Kazi Ahsan, Ahmed, Mita, Shikder   +3 more
core   +1 more source

Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials

Frontiers in Pharmacology, 2022
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million.
Zhenchao Wu, Zhenchao Wu, Zhifei Han, Zhifei Han, Beibei Liu, Beibei Liu, Ning Shen, Ning Shen   +7 more
doaj   +1 more source

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses.
Muhammad Irfan Malik, Sardar Al Fareed Zafar, Muna Malik, Fabiha Qayyum, Iqra Akram, Ammarah Arshad, Khalid Waheed, Jodat Saleem, Abdul Jabbar, Muhammad Junaid Tahir, Zohaib Yousaf   +10 more
doaj   +1 more source

Remdesivir-Bound and Ligand-Free Simulations Reveal the Probable Mechanism of Inhibiting the RNA Dependent RNA Polymerase of SARS-CoV-2 [PDF]

, 2020
The efforts towards developing a potential drug against the current global pandemic, COVID-19, has increased in the past few months. Drug development strategies to target the RNA dependent RNA polymerase (RdRP) are being tried worldwide.
Uddhavesh, Sonavane, Rajendra, Joshi, Shruti, Koulgi, Vinod, Jani, Mallikarjunachari, Uppuladinne V N   +4 more
core   +2 more sources

Direct and Catalytic C-Glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside [PDF]

, 2021
Since early 2020, scientists have strived to find an effective solution to fight SARS-CoV-2, especially by developing reliable vaccines that inhibit the spread of the disease and repurposing drugs for combatting its effects on the human body.
Benjamin, List, Sebastian A., Schwengers, Markus, Leutzsch, Benjamin, Mitschke, Carla, Obradors, Sebastian, Brunen, Miles H., Aukland, Oleg, Grossmann   +7 more
core   +2 more sources

An Analysis of Remdesivir Patenting [PDF]

, 2020
Pharmaceutical patents are categorized into primary patents and secondary patents. Primary patents refer to compound patents, while secondary patents mainly include crystalline form patents, process patent, formulation patent and method of use patent. In
CHANG, Tingbin, WANG, Zhong
core   +1 more source

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, 2023
Background Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs.
Chuizhe Chen, Junde Fang, Shu Chen, Mamy Jayne Nelly Rajaofera, Xuemiao Li, Bo Wang, Qianfeng Xia   +6 more
doaj   +1 more source

Effects of Remdesivir on in-Hospital and Late Outcomes of Patients With Confirmed or Clinically Suspected COVID-19: A Propensity Score-Matched Study

Acta Medica Iranica, 2022
Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi, Ali Ajam, Mahnaz Montazeri, Samira Kafan, Abdolazim Veisizadeh, Morteza Ghoghaei, Sina Kazemian, Arezoo Ahmadi, Fazeleh Majidi, Maryam Moghadasi, Mehdi Kashani, Faezeh Ghasemi, Marzieh Pazoki   +12 more
doaj   +1 more source

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Trials, 2021
Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases.
Stephen I. Walimbwa, Julian P. Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D’Avolio, Mohammed Lamorde   +5 more
doaj   +1 more source

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

iScience, 2021
Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, Timir Tripathi   +3 more
doaj   +1 more source